Buprenorphine/samidorphan, a combination product of buprenorphine and samidorphan (a preferential μ-opioid receptor antagonist), appears useful for treatment-resistant depression. Cocaine dependence
In combination with samidorphan or naltrexone (μ-opioid receptor antagonists), buprenorphine is under investigation for the treatment of cocaine dependence, and recently demonstrated effectiveness for this indication in a large-scale (n = 302) clinical trial (at a high buprenorphine dose of 16 mg, but not a low dose of 4 mg). Neonatal abstinence
Buprenorphine has been used in the treatment of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application. Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days. Obsessive–compulsive disorder
In one study, buprenorphine was found to be effective in a subset of individuals with treatment-refractory obsessive–compulsive disorder. References
External links
"Buprenorphine". Drug Information Portal. U.S. National Library of Medicine. U.S. Federal government buprenorphine program for opioid addiction
Australian national buprenorphine policy
"The bitter pill": A Wired article on Suboxone
"Subu Must Die – How a nation of junkies went cold turkey": A New Republic article on Subutex abuse in the nation of Georgia
References
External links

Dextrocardia at NIHs Office of Rare Diseases
Dextrocardia with situs inversus at NIHs Office of Rare Diseases